From the viewpoint of regulation, this paper investigates the effects of both the Health Care Refonn Act (Gesundheitsreformgesetz, GRG) and the Structural Health Care Act (Gesundheitsstrukturgesetz, GSG) on pharmaceutical markets. Apart from the change in the intensity of regulation, the main...